Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Most people who develop this cancer have chronic liver disease. Treatments typically include surgery, chemotherapy, ...

Recurrence beyond Milan criteria predicts worse outcomes after hepatocellular carcinoma resection. Limited recurrence remains ...

Due to the extremely rare overlap of mitochondrial DNA depletion syndrome type 3 and pediatric hepatocellular carcinoma, the case presents daunting therapeutic challenges.

BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review. Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, driven by marked molecular and clinical heterogeneity and ...

Your liver cells are forgetting how to do their jobs under dietary stress. Here's how that signals cancer risk years before ...

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network In this randomized, open-label, multicenter ...